The primary endpoint of the trial was vasomotor
complaints (ie, hot flashes, night sweats). Other endpoints
included the following: plasma lipids and lipoproteins,
vaginal bleeding and endometrial proliferation,
health-related quality of life, progression of
carotid artery intimal medial wall thickening, brachial
artery endothelial function, and bone density. Additional
measures were also obtained to monitor compliance
and safety of the interventions (eg, mammography,
hospitalizations, and physician visits).